PBM
Psyence Biomedical Ltd. Common SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.71M
P/E Ratio
—
EPS
$-389.98
Beta
0.31
52W High
$74.94
52W Low
$1.92
50-Day MA
$2.85
200-Day MA
$94.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company at the forefront of harnessing the therapeutic potential of psychedelic compounds for mental health and wellness applications. Utilizing a vertically integrated model, the firm engages in the cultivation, formulation, and clinical research of psilocybin and other psychedelics, aiming to develop groundbreaking therapies that effectively tackle mental health challenges. With a robust intellectual property portfolio and a strong clinical pipeline, Psyence is strategically poised to lead in an evolving industry, benefiting from increasing societal acceptance and the urgent need for accessible mental health solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.15M |
| Operating Margin | 0.00% |
| Return on Equity | -74.30% |
| Return on Assets | -34.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $39.62 |
| Price-to-Book | 0.47 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 6.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.29M |
| Float | 292,590 |
| % Insiders | 4.45% |
| % Institutions | 1.43% |
Data last updated: 4/9/2026